FDA Approves Arcutis’ Roflumilast Topical Foam, 0.3% for Seb Derm in Individuals Aged 9 and Older
The U.S. Food and Drug Administration (FDA) has given its nod to topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Arcutis aims to make the foam widely available via wholesaler and dermatology pharmacy channels […]